CLA Shown to Reduce Fat Mass Without Exercise
The outcome of this new study provides substantial insights on the effects of Clarinol CLA since the research was conducted with a sufficient amount of people to demonstrate the effects of CLA for body weight management.
25/05/06 Lipid Nutrition revealed its latest results on Clarinol CLA at the DDW (Digestive Disease Week) 2006 in Los Angeles. New research shows that Clarinol CLA reduces fat mass in particular locations on the body, without any additional exercise. Previous research on CLA was not able to establish this prior to this study. The subjects in the trial lost 2 kg of fat (equal to 4.4 lbs.) around the waist area and in the legs.
The outcome of this new study provides substantial insights on the effects of Clarinol CLA since the research was conducted with a sufficient amount of people to demonstrate the effects of CLA for body weight management. The population consisted of 118 overweight and obese persons (BMI 28-32 kg/m2) and was randomized into two groups: a CLA group and a placebo olive oil group for six months. Not only did the CLA group lose weight, but also lost a significantly amount of fat located in the legs and mid-section.
According to Dr. Sandra Einerhand, Director Nutrition in Europe at Lipid Nutrition and presenter at the DDW 2006, this study proves that Clarinol(TM) CLA shapes the body, "With so many overweight and obese people out there for weight loss, it is important to find healthy ways to decrease body fat." Patrick Luchsinger, Marketing Manager at Lipid Nutrition is confident in the future developments of the CLA market. "This latest research on Clarinol(TM) CLA further supports Lipid Nutrition's commitment to scientifically based ingredients that have a healthy benefit for consumers. We are pleased to inform customers that Clarinol(TM) CLA is the most effective ingredient for weight management that one could include into a product line."
In the Clarinol CLA supplemented group, fat mass reduction was observed after three months. The women in the Clarinol CLA group showed fat reduction located in the leg and waist areas whereas for men the fat reduction was mainly in the waist area/mid-section. Previous research was unable to establish this before. Overall body weight, hip/waist ratio and BMI reduced relative to the placebo.
Additionally, the safety of Clarinol CLA was evaluated by monitoring adverse events and blood safety parameters. Insulin sensitivity was not adversely affected.
